AB Science announces a slight delay in the publication of its 2024 half-year financial report
30/09/2024 – The Company will publish its financial report for the first half of 2024 on Monday 7 October 2024
AB Science announces the success of a 5.0 million euros capital increase
30/09/2024 – AB Science announces today the success of a capital increase by private placement for an amount of 5 million euros
AB Science provides an update on the microtubule program AB8939
26/09/2024 – AB Science today provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024
23/09/2024 – AB Science today provides an update on the development of masitinib in progressive forms of multiple sclerosis (MS), following the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 conference
Positive results of the Phase 2 study evaluating masitinib in Covid-19
08/07/2024 – AB Science today announces the results of a Phase 2 study evaluating masitinib in COVID-19
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
28/06/2024 – AB Science today announces that the CHMP has adopted, in line with the trend vote, a negative opinion on the application for conditional marketing authorization of masitinib in the treatment of ALS
June 26, 2024 CGM – Q&A document
26/06/2024 – Q&A document of the June 26, 2024 Combined General Meeting
Summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
31/05/2024 – AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS
AB Science webcast of May 30, 2024
30/05/2024 – Presentation of the AB Science webcast held on May 30, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
29/05/2024 – AB Science today announces that the CHMP adopted a trending toward a negative opinion on the application for conditional marketing authorisation of masitinib in ALS